Cirius Therapeutics to Showcase CIR-0602K's Cardiometabolic Benefits at CVCT Forum 2025
New data from Phase 2 trials highlight the drug’s potential to support heart and metabolic health.
Cirius Therapeutics, a biotech company pursuing therapies for conditions driven by insulin resistance and metabolic dysfunction, announced that CEO Robert Beardsley, PhD, will present a curated set of findings related to CIR-0602K at the Global Cardiovascular Clinical Trialists (CVCT) Forum 2025. The session is scheduled for Wednesday, December 8, during the panel titled Incretin-Based Weight Management Medicines – Weight Loss and Muscle Health: Hype or Hope. The data to be shared include prior Phase 2 results that point to CIR-0602K’s unique capacity to influence core drivers of cardiovascular health:
Metabolic and Glycemic Regulation
- HbA1c reductions ranging from -0.5% to -1.3% in individuals not at goal, alongside decreases in fasting and postprandial glucose; elevated HbA1c is linked to higher risks of microvascular and macrovascular disease and cardiovascular events.
- Decreases in insulin resistance and fasting insulin by as much as 50%; high insulin levels have associations with vascular disease and major adverse cardiovascular events (MACE).
- These benefits persisted when CIR-0602K was added to stable GLP-1 therapy.
Inflammation
- A roughly 40% reduction in high-sensitivity C-reactive protein (hsCRP) among participants who began with hsCRP above 3 mg/L, a marker associated with higher cardiovascular risk.
Lipid and Vascular Health Markers
- Increases in HDL cholesterol.
- Favorable shifts in lipoprotein particle subtypes (HDL moving from HDL3 to HDL2; LDL transitioning toward larger, less atherogenic particles).
- Lower blood pressure and reductions in endothelin (ProC6).
Body Composition
- Gains in lean muscle mass, strength, and muscle metabolic activity, even in the context of weight-loss therapies that typically reduce muscle. Maintaining healthy muscle is crucial for lowering cardiovascular risk, particularly with aging; preclinical data in diet-induced obese mice showed CIR-0602K counteracting GLP-1–related muscle and mitochondrial losses.
- Beneficial remodeling of white adipose tissue, including smaller adipocytes, a shift from pro-inflammatory to anti-inflammatory profiles, and a beiging effect that enhances metabolic activity. In diet-induced obese mice, CIR-0602K and tirzepatide promoted this remodeling, with a notable synergistic effect when combined.
- Reduction in the visceral-to-subcutaneous fat ratio and in ectopic fat deposits. A higher V/S ratio correlates with more cardiovascular events, and ectopic fat in organs, including the heart, drives inflammation and poorer outcomes.
The forum presentation will also touch on cardiovascular endpoints from a recently announced Type 1 Diabetes Phase 2 program, which may further illustrate CIR-0602K’s benefits.
“Taken together, these data present a compelling narrative about the potential impact of CIR-0602K on cardiovascular outcomes,” commented Dr. Beardsley. “Cardiometabolic health is rooted in mitochondrial function at the cellular level. Our work in diabetes and MASH demonstrates that reprogramming mitochondrial metabolism to combat dysfunction could offer meaningful benefits for patients with or at risk of cardiovascular disease.”
Beyond the presentation, Dr. Beardsley will join a panel discussion on muscle-sparing and building strategies during weight loss, exploring whether such approaches are essential or optional in weight-management regimens.
The CVCT Forum is slated for December 8–10 at the Mayflower Hotel in Washington, DC.
References cited include key studies linking HbA1c and cardiovascular risk, insulin resistance, inflammation, and lipid dynamics, underscoring the breadth of CIR-0602K’s observed effects across metabolic and vascular health domains.
About Cirius
Cirius Therapeutics is a clinical-stage company focused on mitochondrial pyruvate carrier (MPC) inhibition to address metabolic dysfunction underlying insulin resistance and related organ pathologies seen in type 2 diabetes and obesity. CIR-0602K is a first-in-class oral small molecule designed to selectively inhibit MPC, aiming to reprogram mitochondrial energy substrate selection and improve metabolic health. In preclinical and clinical work, MPC inhibition has shown promise in enhancing glycemic control, improving body composition, supporting liver health and fibrosis in MASH, and offering broad cardiometabolic benefits.
About CIR-0602K
CIR-0602K has completed seven US clinical trials, including a 52-week, placebo-controlled Phase 2b study in 392 participants with MASH with or without type 2 diabetes, and a 28-day Phase 2a trial in 129 participants with type 2 diabetes. Across these studies, CIR-0602K reduced HbA1c and insulin levels, mitigated liver injury and MASH, and remained effective when used alongside GLP-1 therapies. A Phase 2b/2a crossover with type 1 diabetes is planned for late 2025, supported in part by Breakthrough T1D initiatives.
Preclinical data also show gains in lean muscle mass, strength, and metabolic function, as well as favorable shifts in adipose tissue toward a metabolically healthier profile. Notably, combining CIR-0602K with GLP-1/GIP dual agonists like tirzepatide produces pronounced adipose tissue remodeling and potential synergy. By targeting MPC—without activating PPAR-γ—CIR-0602K draws on the efficacy profile of early insulin-sensitizers while avoiding their typical side effects.
Directly addressing a core pathophysiology of chronic metabolic disease, CIR-0602K has the potential to become a foundational therapy, especially when combined with GLP-1–based treatments for patients with type 2 diabetes, obesity, MASH, and related cardiometabolic conditions.
Website: www.CiriusTx.com
Contact: media@CiriusTx.com
Source: Cirius Therapeutics
